Table 3.

Kaplan-Meyer analysis of disease-free survival in patients with and without chemotherapy

Scoring system	Without neoadjuvant chemotherapy (group A)					Before neoadjuvant chemotherapy (group B1)					After neoadjuvant chemotherapy (group B2)
	n	Median time (months)	95% CI	3 years (%)	P-value	n	Median time (months)	95% CI	3 years (%)	P-value	n	Median time (months)	95% CI	3 years (%)	P-value
Nordlinger	150	16	12–20	40	0.028a	101	13	9–17	36	0.458a	101	13	9–17	36	0.173a
0–2	87	18	0–43	46		37	13	5–22	38		47	14	7–23	40
3–4	59	15	11–19	34		60	13	6–20	36		53	12	7–17	33
5–6	4	4	0–12	0		4	3	0–9	0		1	–	–	–
Fong	150	16	12–20	40	<0.001	101	13	9–17	36	0.603	101	13	9–17	36	0.096
0–2	123	21	3–39	47		54	13	3–23	38		70	14	6–22	39
3–5	27	10	8–12	11		47	12	7–17	34		31	7	3–11	29
Nagashima	193	14	11–17	35	0.001a	159	9	7–11	26	0.030a	159	9	7–11	26	0.001a
0–1	112	18	10–26	44		61	13	6–20	32		72	14	8–20	34
2–3	77	10	7–13	24		94	7	5–9	22		84	6	5–7	18
≥4	4	11	5–17	0		4	6	–	25		3	6	–	–
Konopke	145	16	11–21	41	0.002	69	21	3–39	45	0.354	69	21	3–39	45	0.663
0	91	37	12–61	51		13	41	–	61		15	41	0–83	59
1	47	14	10–18	29		38	21	0–44	45		46	20	6–34	41
≥2	7	9	0–22	0		18	6	0–14	32		8	6	0–14	38

CI confidence interval, CRS clinical risk score

^aAs a result of the small numbers of patients, CRS subgroup 3 (CRS ≥4) was pooled together with subgroup 2 (CRS 2–3)